Indivior Pharmaceuticals, Inc. Increase (Decrease) in Other Operating Assets
Indivior Pharmaceuticals, Inc. (SUPN) reported Increase (Decrease) in Other Operating Assets of $35.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was $17.00M.
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was $18.00M, a 0.00% change year-over-year.
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating assets for the quarter ending 2025-12-31 was -$11.00M, a 191.67% decline year-over-year.
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was -$7.00M, a 275.00% decline year-over-year.
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating assets for fiscal 2025 was -$49.00M.
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating assets for fiscal 2024 was -$377.00M, a 190.19% decline from fiscal 2023.
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating assets for fiscal 2023 was $418.00M.
- Indivior Pharmaceuticals, Inc. increase (decrease) in other operating assets for fiscal 2022 was -$69.00M.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month | Increase (Decrease) in Other Operating Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $17.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $35.00M 10-Q · filed 2026-08-03 | $24.00M derived: sum of 3 quarters · filed 2026-08-03 | $17.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2026-03-31 | $18.00M 10-Q · filed 2026-04-30 | $7.00M derived: sum of 2 quarters · filed 2026-04-30 | $0.00 derived: sum of 3 quarters · filed 2026-04-30 | -$49.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-12-31 | -$11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$18.00M derived: sum of 2 quarters · filed 2026-02-26 | -$67.00M derived: sum of 3 quarters · filed 2026-08-03 | -$49.00M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$56.00M derived: sum of 2 quarters · filed 2026-08-03 | -$38.00M 10-Q · filed 2025-10-30 | -$26.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-06-30 | -$49.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$31.00M 10-Q · filed 2026-08-03 | -$19.00M derived: sum of 3 quarters · filed 2026-08-03 | -$15.00M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2025-03-31 | $18.00M 10-Q · filed 2026-04-30 | $30.00M derived: sum of 2 quarters · filed 2026-04-30 | $34.00M derived: sum of 3 quarters · filed 2026-04-30 | $37.00M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.00M derived: sum of 2 quarters · filed 2026-02-26 | $19.00M derived: sum of 3 quarters · filed 2026-02-26 | -$377.00M 10-K · filed 2026-02-26 | -$378.00M 10-K · filed 2025-03-03 |
| 2024-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $7.00M derived: sum of 2 quarters · filed 2025-10-30 | -$389.00M 10-Q · filed 2025-10-30 | ||
| 2024-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$393.00M 10-Q · filed 2025-07-31 | |||
| 2024-03-31 | -$396.00M 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | $418.00M 10-K · filed 2026-02-26 | $410.00M 10-K · filed 2025-03-03 | |||
| 2022-12-31 | -$69.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |